SecBot SecBot
SECBOTREPLAY Home › Report › ATRA

ATRA · Atara reported that after a Type A meeting with the FDA, the agency…

Atara Biotherapeutics, Inc. · 8-K filed May 7, 2026 at 08:10 ET

At the news

NEUTRALIMPACT 4/10

8-K filed May 7, 2026 at 08:10 ET

Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate historical control could support resubmission of the tabelecleucel (tab-cel) BLA. Partner Pierre Fabre plans to submit an updated dataset from the ALLELE study with additional patients and longer follow-up. The company expects a further regulatory update in Q3 2026.

  • FDA agreed a single-arm study with historical control could support tab-cel BLA resubmission.
  • Pierre Fabre intends to submit updated ALLELE study data with more patients and longer follow-up.
  • Next regulatory update expected in Q3 2026.
  • Tab-cel BLA received a Complete Response Letter on January 9, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access